News Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Oct 6, 2017First Time Tetrahydrocannabinol (THC) and Palmitoylethanolamide (PEA) To Be Combined in Proprietary FormulationTherapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today...
- Sep 27, 2017THX-ULD01 Being Developed for Treatment of Mild Cognitive Impairment
Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based drugs, today announced...
- Aug 10, 2017- Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT -
Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, today reported financial results for the...
- Aug 3, 2017
Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, announced today that it will host a...
- Jul 11, 2017
CURE Pharmaceutical (OTCQB: CURR), ("CURE"), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company and Therapix Biosciences (NASDAQ: Ltd....
- Jun 27, 2017
Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that the...
-
May 30, 2017
Therapix Biosciences Ltd. (TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, today announced that the Company's management will...
-
May 24, 2017
Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, today announced that following...
-
May 8, 2017
Therapix Biosciences Ltd. (TRPX) ("Therapix"), a specialty clinical stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that it entered into a...
-
May 3, 2017
Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that it has...
-
Apr 5, 2017Agreement Paves the Way for Development and Marketing of New Cannabinoid-based Treatment Offerings for Mild Cognitive Impairment and other Neurological Conditions
Tel-Aviv, Israel, April5, 2017 – Therapix Biosciences Ltd. (NASDAQ, TASE: TRPX), a specialty clinicalstage pharmaceutical company specializing in the development of cannabinoid-based drugs,...
-
Apr 3, 2017
Tel-Aviv, Israel, April 3, 2017 – Therapix Biosciences Ltd. (NASDAQ; TASE: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs,...
-
Mar 27, 20172,000,000 American Depository Shares Priced at $6.00 per ADS
Tel-Aviv, Israel, March 27, 2017 – Therapix Biosciences Ltd. (NASDAQ: TRPX, TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based...
-
Mar 22, 2017
Tel Aviv, Israel, March 22, 2017 – Therapix Biosciences Ltd. (NASDAQ:TRPX) (TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based...
-
Mar 10, 2017
Therapix Biosciences (OTC: THXBY) (TASE: THXBY.TA), a pharma company specializing in the development of cannabinoid-based drugs, signed a non-binding Memorandum of Understandings (MOU) for a...
-
Feb 16, 2017
Therapix Biosciences, a clinical-stage pharma company specializing in the development and commercialization of cannabinoid-based drugs announced that it entered into an agreement with a private...
-
Jan 4, 2017A translation of the Tel Aviv Stock Exchange (TASE) Immediate Release
The Company respectfully updates, that it was informed that on December 23, 2016, the first subject was enrolled into the proof-of-concept phase IIa clinical trial of the drug developed by the...
-
Nov 10, 2016
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA), a pharmaceutical company specializing in the development of cannabinoid-based product candidates, signed a non-binding...
-
Nov 3, 2016Simes has extensive experience in the management of pharma companies in the U.S.
Tel Aviv, Israel. Therapix Biosciences, (OTC: THXBY) (TASE: THXBY.TA) the cannabinoid-based drugs, announced its intention to add Mr. Stephen M. Simes to the Company’s board of directors. Simes...
-
Oct 31, 2016The cannabinoid-based tablet will be used in the upcoming, first clinical trial in its program for the treatment of cognitive impairments
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA) the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced the...
-
Oct 1, 2016
Therapix Biosciences (OTCQB: THXBY) (TASE: THXBY.TA), a clinical-stage pharma company specializing in the development of cannabinoid-based drugs, reported that in its ongoing product portfolio...
-
Jul 4, 2016The technology, developed at the Hebrew University of Jerusalem, facilitates administration and maximal absorption of the active ingredient THC via nasal inhalation
Tel Aviv, Israel. Therapix Biosciences, , (OTCQB: THXBY) (TASE: THXBY.TA), a pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced today that...
-
Jun 21, 2016Such technology facilitates the administration and maximal absorption of the active ingredient THC via a sublingual tablet, with a view to provide a response for the indications on which the Company has chosen to focus
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA), the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced today...
-
Jun 15, 2016The application was filed after completion of the pre-clinical phase and proof-of-concept of the entourage technology and further to the Company’s preparations towards clinical trials in humans
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA) the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced that it filed...
-
Jun 13, 2016
Tel Aviv, Israel. Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA) the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced that five...
-
Feb 17, 2016The Company successfully completed the preclinical episode of the “Joint-Pharma” program, which is aimed at the development of a product combining cannabinoid substances for treating neurological disorders, with an emphasis on Tourette’s syndrome under an orphan drug designation
Therapix Biosciences announces on February 17th, 2016 of successful results in preclinical studies it has conducted in order to confirm the “entourage effect”. The preclinical study examined...
-
Feb 16, 2016Therapix is using technology developed at the Faculty of Medicine of Tel Aviv University, in the context of the Company’s Brain-Bright Program
Therapix, a specialty pharma company engaged in the development of cannabinoid-based prescribed drugs, announced on February 15th, 2016 that it has entered into a definitive agreement with Ramot,...
-
Dec 22, 2015Rhodes Technologies, a Purdue Pharma group company, will supply Therapix with API for the R&D activity, in consideration for a future exclusive supply right and a right of negotiation to marketing the product in the U.S.
Therapix Biosciences, a company engaged in the development of cannabinoid-based drugs, announces that it has signed an unbinding term-sheet with Rhodes Technologies, a Purdue Pharma group company,...
-
Dec 9, 2015Prof. Mechoulam, the “father of medical cannabis” is one of the industry’s pioneers, and was the first to describe the “entourage effect” which serves as basis for one of the Company’s technologies
Therapix Biosciences announces the appointment of Prof. Raphael Mechoulam as member of the Company’s scientific advisory board, further to the decision to focus the Company’s business strategy...
-
Dec 9, 2015Dr. Elran Haber was appointed CEO of the Company and Doron Ben Ami was appointed VP Strategy of the Company
Therapix, a company engaged in the development of drugs based on the active compounds in cannabis, announces today of key appointments to the Company’s management. Dr. Elran Haber was appointed...
-
Oct 26, 2015The investment agreements include a private placement to investors at NIS 1.05 per share, for a total of approx. NIS 3.3 million. In addition, the investors signed agreements for the exercise of options granted in the context of the Dekel transaction, for approx. NIS 2.3 million.
Therapix, a company engaged in the development of cannabinoid-based drugs, announces today that it had entered into a series of investment agreements for a total of approx. NIS 5.6 million. The...
-
Aug 16, 2015
The Company wishes to update, in respect of the Company’s investment agreement in LaraPharm Ltd., that further to discussions recently held between the Company and LaraPharm’s management, the...
-
Aug 15, 2015The Company and Dekel Pharmaceuticals Ltd. ("Dekel") have signed a definitive exclusive royalty baring license agreement regarding Dekel's technology, IPs and knowhow. The Company granted Dekel an option for investing in the Company at predefined terms. The agreement was approved by the ISA and TASE.
The Entourage Effect Cannabinoids are a diverse group of chemical compounds that operate on specific receptors in the body (CB1 and CB2). This family includes molecules that are derived from the...
-
Aug 4, 2015In the last several decades, no new drug was developed or launched for treating Tourette's syndrome. Tourette's syndrome is a neurological disorder characterized by involuntary movements and vocalizations.
Further to Therapix Biosciences’ strategic plan determined at the beginning of 2014, the Company announced to investors this morning that the Company’s Board of Directors has decided to focus...
-
Jun 28, 2015Entered into an MOU with the University’s tech-transfer company, whereby it shall fund a research project for developing and adapting a technology related to low dosages of THC for treating cognitive functioning impairments.
Therapix Biosciences announces that it has entered into a non-binding memorandum of understandings with Ramot, Tel Aviv University’s technology transfer company, whereby the Company shall fund a...
-
Mar 30, 2015
Further to the management’s efforts to raise capital for the company, Therapix announces an agreement with an unrelated private investor for a private placement of NIS 2.2 million for 4,400,000...
-
Jan 12, 2015
TEL AVIV, Israel, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Therapix Bio (TASE:THXBY) (OTCQB:THXBY) today announced that it has entered into a binding Term Sheet outlining a licensing and royalty...